Semax

In a podcast on peptide channel takedowns, Dylan Gemelli names Selank and Semax as two peptides he considers underdiscussed, framing them as options for anxiety and stress and citing a family history of anxiety plus dissatisfaction with conventional anxiolytic treatment. He predicts attention will move past GLP-1s toward peptides targeting the mind, heart, liver and kidneys. No dosing, route, cycling, or outcome data is provided, and the speakers state the compounds are discussed for research purposes only. This is opinion and market commentary, not clinical evidence.

The speaker concludes by directing viewers to seek a medical team for proper prescription and individualized selection between Selank and Semax. This implies the compounds require or benefit from professional oversight rather than self-directed use. No safety contraindications are explicitly detailed.

The speaker references nasal spray as the delivery format for both Selank and Semax, implying intranasal administration is the standard or preferred route discussed in this context. No specific dosage, concentration, or spray frequency is mentioned.

The speaker recommends resolving sleep issues and systemic inflammation as foundational steps before introducing either Selank or Semax. This is framed as a prerequisite to ensure the peptides function as precision tools rather than expensive guesses. No specific sleep or inflammation protocols are detailed.

The speaker explicitly cautions against stacking both Selank and Semax by default, stating that doing so may result in paying for a signal the user does not need. The recommendation is to identify the specific cognitive gap first and use only the peptide that addresses it. No dosage information is provided.

The speaker argues that Selank and Semax address opposite cognitive bottlenecks — low arousal/fog versus high arousal/anxiety — and that users should select only the compound matching their specific problem. The framing is that the two peptides are not interchangeable or redundant, and choosing incorrectly wastes money on an unneeded signal.

Semax is described as pushing Brain-Derived Neurotrophic Factor (BDNF), characterized as 'fertilizer for neurons.' This mechanism is said to sharpen focus, recall, and drive. It is positioned as the appropriate tool when the user experiences mental flatness or brain fog.

Dihexa and Semax were scheduled for day two of the FDA Pharmacy Compounding Advisory Committee meeting. Dr Alex reports from the meeting that the committee recommended moving BPC-157, TB-500, KPV and MOTS-c to the 503A bulk list, which if formally accepted could restore compounded prescription access by the end of 2026. He states the remaining three compounds - epitalon, dihexa and Semax (rendered 'C-max' in the auto transcript) - were on the agenda for the following day, so their outcome is not yet decided in this video. The FDA livestreamed the session. This is advocacy and regulatory reporting from the American Academy for Peptide Medicine side, not clinical evidence on Dihexa or Semax, and the day two result still needs confirmation.

Overview of the FDA/PCAC peptide landscape. Describes Semax (as C-Max) as a stroke-recovery/cognitive agent, Selank as a non-sedating anxiolytic, and Dihexa as a potent synaptogenic compound (technically not a peptide). Context on the 2023 gray-market shift and PCAC scheduling.

Clinician-oriented Semax guide. Indications: cognitive/memory enhancement, anxiety/depression, ischemic stroke and brain-injury recovery, ADHD, neuroprotection, optic nerve disorders, chronic fatigue, pain. Mechanisms: raised BDNF, dopaminergic/serotonergic modulation, improved cerebral blood flow, antioxidant effects, melanocortin receptor binding. Dosing: nasal 300-1000mcg/day (up to 3000), SC 100-500mcg/day (up to 1000), 10-14 day cycles. Caution in bipolar disorder, avoid in pregnancy. Expert clinical explanation.

Long-form Semax deep dive framing the Russian heptapeptide nasal spray as a real-world nootropic for cognitive enhancement and neuroprotection against stroke damage; reviews largely Russian-language literature. Creator opinion, not primary evidence.

Explainer on Semax mechanism: a 7-amino-acid ACTH(4-10) analog that raises BDNF to strengthen synapses, improving learning, memory and cognition; noted use in stroke and brain-injury research. Educational/creator opinion.

The speaker repeatedly uses the qualifier 'hypothetically' when stating peptide dosages (SS-31 at 2 mg/day, MOTS-c at 1 mg/day, Semax at 400 mcg/day), framing the recommendations as hypothetical for a 'kangaroo' rather than direct human prescriptions. This appears to be a legal disclaimer strategy. The dosages are nonetheless presented with specificity and clinical intent within the context of a burnout recovery protocol. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

The speaker provides a specific expected timeline for Semax's effect on dopaminergic system recovery, stating that the 'choice gap' — the ability to pause between stimulus and response indicating restored prefrontal cortex and dopamine function — should return within approximately two weeks on the protocol. If the patient is still reactive and running on fumes at two weeks, the speaker suggests the protocol needs tweaking. This is framed as a subjective but clinically meaningful biomarker of neurochemical recovery. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

The speaker issues a direct warning against stacking too many compounds simultaneously, including peptides, citing the example of patients taking 14+ supplements including 'a whole bunch of peptides.' He argues this creates metabolic chaos, overloads the liver and kidneys, and adds additional processing burden to already-failing mitochondria. The warning is framed as a safety and efficacy concern: more compounds do not equal more optimization and can actively worsen the underlying mitochondrial failure being treated.

The speaker presents a comprehensive multi-compound protocol targeting each biochemical mechanism of burnout: SS-31 (2 mg/day) and MOTS-c (1 mg/day) for mitochondrial repair; NAD+ (50 mg/day) for electron transport and DNA repair enzyme activation; CoQ10 (200 mg/day) and PQQ (20 mg/day) for electron carrier substrate and biogenesis signaling; L-Tyrosine (3 g/day) as dopamine/norepinephrine precursor; Semax (400 mcg/day morning) for BDNF-mediated dopaminergic recovery; Magnesium Bisglycinate (500 mg before bed) as NMDA antagonist; and L-Theanine (200 mg before bed) for GABA promotion and glutamate excitotoxicity reduction. The speaker states this protocol takes 20–30 days. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

The speaker makes a specific safety and mechanistic distinction that 'Semax' does not act as a dopamine releaser or amphetamine-like stimulant, contrasting it with Adderall, Ritalin, and energy drinks that force dopamine output and deplete reserves. This is framed as a critical differentiator for burned-out patients whose dopamine synthesis enzymes and BH4 cofactors are already depleted. Using a stimulant in this state worsens the underlying biochemical deficit, whereas Semax works through a restorative BDNF pathway. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

The speaker recommends a compound referred to as 'Semax,' clarifying it is not a dopamine releaser or amphetamine and does not force output. It is described as working through BDNF (Brain-Derived Neurotrophic Factor) signaling to grow new neuronal connections and recover the dopaminergic system. A dosage of 400 micrograms every day in the morning is specified. The speaker emphasizes it restores dopamine system integrity without forcing depletion of existing stores. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

Semax appears to activate the default mode network, the brain region involved in creativity, visualization, and problem solving. Users report enhanced visual thinking and creative flow. This is a less studied effect but consistently reported anecdotally.

Ben Greenfield mentions using an intranasal peptide called 'Semax' (likely a phonetic reference, possibly 'Semax' or a similar nootropic peptide) to compensate for poor sleep and maintain cognitive performance during the podcast recording. No dosage is specified. This is presented purely as a personal anecdotal use case with no clinical data cited. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]

The speaker discloses that he owns Elite Biogenics, the company from which he sources the compounds discussed in the protocol including peptides. He states the company has its own labs and warehouses and that he personally trusts the products enough to give to his family. This is a relevant conflict-of-interest disclosure for evaluating the objectivity of the peptide recommendations made throughout the video.

Semax has 30+ years of clinical use in Russia with no major safety signals. Does not affect cortisol or hormonal system. Not habit-forming, no withdrawal issues. Possible side effects: nasal irritation (intranasal), temporary nasal cavity discoloration, headaches (often from dehydration or high dose), sleep disruption (if taken late). Less common: blood glucose elevation in diabetics, blood pressure increase at higher doses, mood changes/irritability. Contraindicated with MAO inhibitors, uncontrolled hypertension, pregnancy/breastfeeding, and psychiatric conditions (especially mania or severe anxiety).

For cognitive support: 200-600mcg/day intranasally (1-2 drops per nostril depending on concentration), once or twice daily. Cycle 10-14 days on, then break of several weeks to months. Not for year-round continuous use due to BDNF pathway adaptation and diminishing returns. Take early morning or early afternoon to avoid sleep disruption. Semax is on Russia's list of vital and essential drugs since 2011.

A 1995 study from the Institute of Molecular Genetics showed Semax given 20 minutes before amphetamine dramatically increased dopamine release compared to amphetamine alone. Semax potentiates dopamine release rather than directly spiking it. This explains why caffeine reportedly works better during Semax use, and why users feel more interested in things without jitteriness. Also increases serotonin turnover rate, explaining mood stability benefits.

A single dose of Semax increases BDNF protein levels by approximately 40% and increases BDNF gene expression by about 3x. Effects begin within 20 minutes, peak around 90 minutes, and last 20-24 hours. Also activates the TrkB receptor that BDNF binds to. This rapid BDNF elevation is the primary reason it was developed for stroke recovery.

Russian clinical trial data shows 70-80% therapeutic efficacy for Semax in treating vascular, inflammatory, and toxic optic nerve conditions, with improvements in visual acuity, visual field, and color vision.

A 2007 study of healthy men performing cognitive tasks showed the Semax group achieved 71% accuracy on memory tests versus 41% for the control group. All human clinical research comes from Russia with no published Western clinical trials. Sample sizes are smaller than typical FDA approval standards.

Gusev et al. (2018) studied 110 ischemic stroke patients given 6000mcg/day Semax for 10 days, then 20-day break, then another 10-day course. Results: plasma BDNF levels increased and stayed elevated, motor performance improved on standardized testing, functional independence improved on Barthel Index. A separate 2001 study of 30 acute stroke patients showed Semax accelerated neurological function recovery, particularly motor function.

Semax and Selank have become strong options for post-traumatic concussions and TBIs (traumatic brain injuries). Their neuroprotective compounds help brain cells rewire and refire. By age 9, the average person has had dozens of minor brain injuries; cumulative subconcussive impacts cause significant long-term problems. These peptides help address the accumulated neurological damage.

Recommended cycling approach: stay on for 6 weeks, off for 1 week, then cycle back. Some users experience a honeymoon phase where potency decreases over time, addressed by dose adjustment or cycling. Oral consumption at lower doses produces fewer side effects than nasal/injection routes and may give better results with daily use. Side effects at higher doses (nasal/injection) can include headaches, nausea, and anxiousness.

Semax has demonstrated anti-anxiety and anti-depressant effects after 14 days of treatment, attributed to BDNF expression in the hippocampus and serotonin modulation. Also shown to improve heart function and reduce risk of heart failure. Additionally upregulates expression of over two dozen genes that regulate immune function. A study of 187 people with cerebrovascular insufficiency showed Semax slowed disease progression and stroke risk.

Semax improves brain function and network firing in patients with blood sugar issues. Type 2 diabetes can progress to type 3 diabetes (early onset Alzheimer's) when inadequate cerebral blood flow impairs neural pathway function. Semax increases blood flow and helps neural pathways rewire, addressing a root cause of metabolic-related cognitive decline.

In 2009, the Russian Federation Ministry of Health approved both Semax and Selank for human consumption. Both are generally recognized as safe globally. Delivery method determines classification: oral = supplement, intranasal or injection = drug. New phyto-microencapsulated nanotechnology and crystallization technology now enable oral peptide delivery with absorption comparable to injection.

Research shows Semax increases BDNF levels by 1.4 times and doubles the expression of certain neuroprotective genes. BDNF stimulation is considered the holy grail for eliminating brain fog and mitigating neurocognitive decline, Alzheimer's, dementia, and Parkinson's. Also works through GABA and opioid receptor binding, which may explain pain-reducing effects alongside cognitive benefits.

Semax is generally well tolerated. Possible side effects include mild nasal irritation, headaches, restlessness, and slight anticoagulant effects. Use caution in patients with severe psychiatric disorders, particularly bipolar disorder. Not recommended for pregnant or breastfeeding women due to limited safety data.

Semax works through multiple pathways: increases BDNF for neuronal growth/protection, modulates dopaminergic and serotonergic systems for mood and cognition, improves cerebral blood flow, has antioxidant properties protecting against oxidative stress, binds melanocortin receptors (MC3/MC4) as antagonist/partial agonist, and inhibits enkephalinase enzymes to prolong natural regulatory peptides. Molecular structure: synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, MW 861.98.

Clinical indications: cognitive enhancement, anxiety/depression management, ischemic stroke recovery, ADHD, neuroprotection, optic nerve disorders, chronic fatigue, and pain management. Nasal spray dosing: start 300mcg/day, maintain 300-1000mcg, up to 3000mcg. SubQ dosing: start 100-200mcg/day, maintain 200-500mcg, up to 1000mcg. Treatment duration typically 10-14 days, repeatable.

Semax is used as an intranasal spray rather than injection or pill form. Intranasal delivery gets the peptide to the brain faster and more directly. Generally well-tolerated with low side effect reporting and smooth cognitive support without negative stimulant side effects.

Semax and Selank are described as sister peptides with different primary applications. Selank is more helpful for anxiety and depression (psychiatric-focused), while Semax targets brain fog, attention, high cognitive demand, and neuroprotection. Semax is recommended for improving learning, focus, and cognitive performance.

Semax enhances focus, learning, and mental clarity without stimulant properties. Unlike caffeine or amphetamines, it does not increase blood pressure or produce a wired feeling. Users report improved task performance, better mental endurance, enhanced clarity, and reduced cognitive fatigue. It works through BDNF upregulation and the dopaminergic system.

Semax has decades of clinical use in Russia for stroke, brain injury, and vascular disorders with zero reported adverse events. Described as one of the safest pharmacological agents ever developed for the brain, with published data across multiple journals.

Dr. Bachmeyer claims nasal spray administration of Semax is ineffective, stating nasal membranes are not designed to transport peptides adequately. This view contradicts most other clinical sources and the standard Russian clinical protocol which uses intranasal delivery. SubQ injection implied as the preferred route.

Recommended cycling protocol is 4 weeks on, 2 weeks off to prevent receptor downregulation and maintain efficacy. Continuous use is not recommended. For maximum cognitive benefit, combine with Cerebrolysin (direct neurotrophic factor infusion), Alpha-GPC (choline/acetylcholine precursor), BPC-157 (systemic inflammation reduction, gut healing, angiogenesis), and GHK-Cu (copper peptide modulating 4000+ genes for DNA repair and tissue remodeling).

Semax applications in neurodegeneration: For Alzheimer's, enhances non-amyloidogenic pathway, reduces toxic peptide production, upregulates neprilysin to degrade existing amyloid. For dementia, BDNF surge activates TrkB receptors promoting neuronal survival and preventing apoptosis. For MS, re-educates immune system shifting cytokine profile from pro-inflammatory TH1/TH17 to regulatory TH2/T-reg while promoting oligodendrocyte progenitor differentiation to rebuild myelin. For Parkinson's, upregulates tyrosine hydroxylase (rate-limiting enzyme in dopamine synthesis) and protects against mitochondrial toxins.

Semax targets three fundamental biological failures causing cognitive decline: (1) Inflammatory firestorm — reduces NF-kappa-B signaling and pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) that cross the blood-brain barrier. (2) Energy famine — enhances expression and sensitivity of glucose transporters (GLUTs) in the brain and improves insulin signaling. (3) ATP shortage — upregulates mitochondrial biogenesis via PGC-1alpha pathway and enhances antioxidant defense (glutathione production).

Semax binds to melanocortin receptors MC3 and MC4 in the hippocampus and prefrontal cortex, initiating transcriptional upregulation of genes coding for BDNF and NGF. This constructs physical infrastructure for better memory and neural pathways rather than just stimulating neurotransmitters. Also upregulates neurogenesis via CREB signaling pathway, pushing neural stem cells to differentiate into functional neurons.

Semax is a seven amino acid synthetic peptide analog of ACTH (not FDA approved). Its primary proposed mechanism is increasing the activity and abundance of BDNF (brain-derived neurotrophic factor), which strengthens synapses between neurons, leading to improvements in learning, memory, and cognitive function.

Supplement formulator compares neuropeptides to traditional nootropics. Dihexa described as 'hundreds of times more powerful than lion's mane' for neurogenesis. P21+Dihexa combined in 'Neurorigen' product. Semax compared to alpha-GPC but far more potent. All peptides positioned as tools to combat neurodegenerative disease beyond what supplements alone can achieve. Also discusses dopamine resensitization via Semax, P21, Dihexa.